Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides

US7081449B2 · kind B2 · utility

Assignee

• Valeant Research & Development · US

Inventors

• Zbigniew Pietrzkowski · Aliso Viejo, US
• Guangyi Wang · Carlsbad, US
• Johnson Yiu-Nam LAU · Houston, US
• Zhi Hong · Chapel Hill, US
• Jean-Luc Girardet · San Diego, US
• Esmir Gunic · San Diego, US

Key dates

• Filing date: Jul 3, 2001
• Grant date: Jul 25, 2006
• Expiry date: Oct 7, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07H19/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A purine nucleoside analog includes a pyrido[2,3-d]pyrimidine or a pyrimido[4,5-d]pyrimidine and further has a sugar moiety that is optionally modified at the C2′, C3′, C4′ and/or C5′ position. Particularly contemplated compounds also include prodrug forms of the purine nucleoside analogs, and both purine nucleoside analogs and the corresponding prodrugs are employed in the reduction of growth of neoplastic cells.